Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Familial Hypercholesterolemia Treatment & Management

  • Author: Mose July, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
 
Updated: Jul 10, 2016
 

Medical Care

The National Cholesterol Education Program (NCEP) ATPIII defined LDLc goals and cutpoints for therapeutic intervention based on risk for CHD (see Table 2 and Table 3).[6, 7]

The guidelines were updated in 2004 to reflect the findings of several interventional trials demonstrating that coronary event rate was reduced after lowering the LDLc well below 100 mg/dL.[8]

The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) have also released guidelines for the management of dyslipidemias, available at the ESC site.[27]

In addition, the American College of Cardiology/American Heart Association (ACC/AHA) released blood cholesterol guidelines, in 2013; however, they do not address a specific approach to and management of FH.[28] .

Next

Risk Categories

CHD or CHD risk equivalent

See the list below:

  • Clinical CHD
  • Symptomatic carotid artery disease or carotid stenosis greater than 70%
  • Peripheral artery disease
  • Abdominal aortic aneurysm
  • Diabetes
  • Global 10-year risk of major CHD event (ie, fatal or nonfatal myocardial infarction) greater than 20%

Determination of risk

Treatment of elevated LDLc levels is based upon the risk for a coronary heart disease (CHD) event (see Table 1). The 2001 National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII) defined target LDLc levels and levels based on risk for CHD.[6] The 2004 update added optional lower LDLc goals to reflect the findings of several interventional trials demonstrating that more aggressive LDLc lowering further reduced coronary event rate.[8]

In patients without atherosclerotic disease, the risk for developing CHD is defined by the number of major risk factors for CHD and by the following:

  • Hypertension (blood pressure ≥140/90 mm Hg or treatment for hypertension)
  • Cigarette smoking (any within the past mo)
  • HDLc level below 40 mg/dL
  • Male sex and age 45 years or older
  • Female sex and age 55 years or older
  • Family history of premature CHD: Clinical CHD or sudden death in first-degree male relative younger than 55 years or first-degree female relative younger than 65 years

An HDLc level of 60 mg/dL or greater is a negative risk factor for CHD and its presence removes one risk factor from the total.

Percent risk for developing CHD or having a major CHD event (ie, fatal or nonfatal myocardial infarction) is determined by calculating the Framingham risk score, which is available through the US National Heart, Lung, and Blood Institute (see Risk Assessment Tool for Estimating 10-Year Risk of Developing Hard CHD).

  • LDLc goal less than 100 mg/dL
  • Therapeutic lifestyle changes (TLC) instituted at LDL 100 mg/dL or more
  • Medical therapy initiated at LDL 100 mg/dL or more (new 2004 cut off point)

Optional LDLc goal less than 70 mg/dL, especially for very high risk patients include the following:

  • Patients with CHD and multiple other major risk factors for CHD, especially diabetes
  • Severe, poorly controlled risk factors, especially continued cigarette smoking
  • Multiple risk factors of the metabolic syndrome
  • Patients admitted with an acute coronary syndrome

Moderately high risk, more than 2 risk factors

See the list below:

  • See Table 2
  • Global risk 10-20% - LDLc goal less than 130 mg/dL, optional LDLc goal less than 100 mg/dL
  • Consider medical therapy for LDL 100-129

Moderate risk, 2 risk factors or more

See the list below:

  • Global risk less than 10% - LDLc goal less than 130 mg/dL

Low risk

See the list below:

  • None to 1 major risk factor for CHD
  • LDLc goal less than 160 mg/dL
  • Low-risk patients have fewer than 2 risk factors and a 10-year risk for a major CHD event that is almost always less than 10%. The goal LDLc is less than 160 mg/dL.
  • Moderate risk patients have 2 or more factors and a 10-year risk for CHD of less than 10%. The goal LDLc is less than 130 mg/dL.
  • Moderately high risk patients have 2 or more risk factors and a 10-year risk of 10-20%. The goal LDLc is less than 130 mg/dL and the update suggested an optional goal LDLc of less than 100 mg/dL.

The highest category of risk includes CHD and CHD risk equivalents include the following:

  • Clinical CHD
  • Symptomatic carotid artery disease (transient ischemic attack or stroke of carotid origin)
  • Peripheral artery disease
  • Abdominal aortic aneurysm
  • Diabetes
  • 10-year risk less than 20%

The LDLc goal for high-risk patients is less than 100 mg/dL and the 10-year risk is greater than 20%. In addition to lifestyle changes, institution of medication is recommended if LDLc level is greater than 100 mg/dL. Patients at high or very high risk have an optional LDLc goal of less than 70 mg/dL.

Patients with cardiovascular disease who are at very high risk have an optional LDLc goal of less than 70 mg/dL.

Very high risk is defined as the presence of the following:

  • Multiple other major risk factors for CHD, especially diabetes
  • Severe, poorly controlled risk factors, especially continued cigarette smoking
  • Multiple risk factors for the metabolic syndrome (especially triglycerides >200 mg/dL, non-HDLc >130 mg/dL, and HDLc < 40 mg/dL)
  • Patients with acute coronary syndromes

Table 1. LDLc Target levels and levels Indicating Therapeutic Lifestyle Changes (TLC) and Drug Therapy (Open Table in a new window)

 



Risk Category



 



LDLc Target level,



mg/dL



 



LDLc level Indicating TLC,



mg/dL



 



LDLc level for Considering Drug Therapy,



mg/dL*



High risk:



CHD or CHD risk equivalent



(10-y risk >20%)



<100



Optional goal <70



>100 >100
Moderately high risk:



More than 2 risk factors



(10-y risk 10-20%)



130



Optional goal <100



>130 >130



(100-129 may consider drug options)



Moderate risk:



More than 2 risk factors



(10-y risk 10%)



<130 >130 >160
Lower risk:



0-1 risk factor



<160 >160 >190



(160-189 LDL-lowering drug optional)



*The 2004 update recommended that when statin therapy is initiated in patients at high or moderately high risk, a dose and strength should be chosen that achieves at least a 30-40% LDLc reduction (see Table 3).

 

Previous
Next

Treatment Recommendations for Homozygous FH

In July, 2014, the EAS published a consensus statement for the screening and treatment of homozygous FH. The treatment recommendations are summarized as follows:[29]

  • Treatment of homozygous FH involves a combination of lifestyle changes, statin therapy, and lipoprotein apheresis, if available, and should be started as early as possible.
  • LDL apheresis should begin as early as age 5 years and no later than age 8 years.
  • For homozygous FH patients, the LDL cholesterol targets are <100 mg/dL for adults, <70 mg/dL for adults with clinical CVD, and <135 mg/dL for children.
  • Two novel agents for LDL cholesterol lowering, lomitapide and mipomersen, can be considered as adjunctive treatments for patients who do not achieve the recommended LDL cholesterol targets and remain at high cardiovascular risk.

General treatment recommendations are discussed in more depth below.

Because of improved diet normally results in upregulation of LDL receptors, the impact of diet changes on LDLc levels in homozygous patients is negligible (there are no receptors to upregulate), but lifestyle changes have other cardiovascular benefits and should be strongly encouraged.[9, 10]

Because of the severity of CHD and lack of response, homozygous FH patients require heroic intervention.

Occasionally, the LDL receptors retain some degree of function and diet control and high doses of HMG-CoA reductase inhibitors combined with bile acid sequestrants, ezetimibe, and niacin can be effective.[11] Estrogen replacement therapy in postmenopausal women is also effective, but this therapy is not recommended because of its adverse effects in older women. However, in some women the benefits may outweigh risks.

The FDA approved Liptruzet (Merck)–a combination of ezetimibe and atorvastatin–for the reduction of cholesterol levels in patients with homozygous FH, and as an adjunct to dietary changes in the treatment of elevated LDLc levels in patients with primary or mixed hyperlipidemia. A once-daily tablet, Liptruzet contains 10 mg of ezetimibe combined with 10, 20, 40, or 80 mg of atorvastatin.[30]

When the LDL receptors are absent or nonfunctional, one of the following is necessary:

LDL apheresis for homozygous FH involves selective removal of lipoproteins that contain apo-B by heparin precipitation, dextran sulfate cellulose columns, or immunoadsorption columns. All methods reduce LDLc levels more than 50% and also lower lipoprotein (a), VLDL, and triglyceride levels. HDL is spared. The procedure takes 3 or more hours and is performed at 1- to 2-week intervals. Few adverse events are experienced, most of which are noncritical episodes of hypotension. LDL apheresis is an extremely expensive procedure and is not readily available.[31, 32]

Portacaval anastomosis

Compared to liver transplantation (see Surgical Care), this procedure is less hazardous and requires no immunosuppression.

Although cholesterol levels are not reduced as dramatically when compared with transplantation or apheresis, the clinical benefits appear comparable.

LDLc reductions 50% have been reported; regression of coronary lesions, aortic lesions, and xanthomas have been documented.

The exact mechanism by which LDLc is lowered is unclear.

Other treatments for homozygous FH

Evolocumab

Evolocumab (Repatha) was approved in August 2015. It is indicated as an adjunct to diet and other LDL-lowering therapies (eg, statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C in adults and adolescents aged 13-17 years. It is also indicated for heterozygous FH in adults.

Approval of evolocumab was based on the Open-Label Study of Long-term Evaluation Against LDL-C (OSLER) study. During approximately 1 year of therapy, the use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels.[33, 34] Additionally, the rate of cardiovascular events at 1 year was reduced from 2.18% in the standard-therapy group to 0.95% in the evolocumab group (hazard ratio in the evolocumab group, 0.47; 95% confidence interval, 0.28 to 0.78; P=0.003) in a prespecified exploratory analysis.[33] Results of the ongoing FOURIER trial is looking at cardiovascular outcomes and will include more than 27,000 patients with clinically evident cardiovascular disease and is expected to be completed in late 2017.[35]

Lomitapide

Lomitapide (Juxtapid) is a first-in-class microsomal triglyceride transfer protein (MTP) inhibitor. It was approved by the FDA in December 2012 as an adjunct to a low-fat diet and other lipid lowering treatments, including LDL apheresis where available, to reduce LDL-C, TC, apo B, and non-HDL-C in patients with homozygous familial hypercholesterolemia. Because lomitapide increases risk of hepatotoxicity, it is only available through a restricted access program. Approval was based on a small trial of 29 patients exposed to lomitapide, with 23 patients exposed to the drug for 1 year, 15 patients exposed for 2 years, and 5 patients exposed for 3 years. At baseline, the mean LDL cholesterol in the homozygous FH patients was 336 mg/dL, and this was reduced 50% after 26 weeks of treatment (P < 0.0001).[36]

Mipomersen

Mipomersen (Kynamro) is an antisense oligonucleotide inhibitor targeting mRNA for apolipoprotein B-100. It was approved by the FDA in January 2013 as an adjunct to lipid-lowering medications and diet to reduce LDL-C, apoB, TC, and non-HDL-C in patients with homozygous FH.[37] Safety and effectiveness as an adjunct to LDL apheresis have not been established.

Approval was supported by the largest clinical trial conducted to date in the homozygous FH patient population. The randomized, double-blind, placebo-controlled, multicenter trial enrolled 51 patients aged 12-53 years, including 7 patients aged 12-16 years, who were maintaining a regimen of maximally tolerated lipid-lowering medications. Treatment with mipomersen further reduced LDL-C levels by an average of 113 mg/dL, or 25%, from a treated baseline of 439 mg/dL, and further reduced all measured endpoints for atherogenic particles.[38]

In December 2012, however, the European Medicines Agency (EMA) recommended against approval of mipomersen for the treatment of homozygous and severe heterozygous FH because of its risk profile, which includes cardiovascular risks, malignancies, immune-mediated reactions, and hepatic abnormalities.

Probucol

Probucol, a medication with only mild LDL-lowering effects and an undesirable HDL-lowering impact, has been shown to cause regression of cutaneous and tendon xanthomas in patients with both homozygous and heterozygous FH. An animal model has demonstrated reduced coronary atherosclerosis. No long-term benefits have been documented for patients with FH.

Gene therapy

Gene therapy is still at the investigational stage. Initially, expectations were high that genetic manipulation would be a less hazardous method for providing functional LDL receptors compared with liver transplantation; however, advances have been slow.

Previous
Next

Treatment for Heterozygous FH

In patients with heterozygous FH, lifestyle modification should always be instituted but is unlikely to result in acceptable LDLc levels; therefore, cholesterol-lowering medication (usually more than one) is necessary.[10]

The 2013 European Atherosclerosis Society (EAS) consensus statement for screening and treatment of heterozygous FH includes the following treatment recommendations[4, 5] :

  • An LDL target of <3.5 mmol/L (<135 mg/dL) for children with FH (age 8–10);
  • An LDL target of <2.5 mmol/L (<100 mg/dL) for adults with FH; and
  • An LDL target of <1.8 mmol/L (<70 mg/dL) for adults with known CHD or diabetes.

Lifestyle modifications include a diet that severely limits saturated fats, trans fats, and cholesterol (see Table 2).[9]

Desirable weight should be attained. Significant weight loss should improve all lipid parameters (LDLc, HDLc, triglycerides).

Aerobic and toning exercises improve blood lipid levels if performed for longer than 30 minutes, 4 or more days per week.

While these efforts often have only a modest impact on LDLc levels, rigorous dietary intervention works synergistically with lipid-lowering medications, especially diet.[9]

With 50% functional LDL receptors, heterozygous FH patients have an excellent response to the usual cholesterol-lowering drugs, but treatment still remains difficult.

To approach the recommended LDLc goals, a high dose of one of the 3 strongest HMG-CoA reductase inhibitors (statins), simvastatin, atorvastatin, or rosuvastatin, and one or more other LDL lowering medications, bile acid sequestrants, ezetimibe, or niacin, is recommended.[11] To decrease the risk of myopathy, one step below the maximum dose of the statin should be considered. For additional resources, please visit Landmark Statin Trials.

Because doubling the dose of any statin lowers the LDLc only 6-7%, adding a second, third, or even fourth agent is more effective.[39]

A pooled analysis of 5 statin trials revealed that intensive-dose therapy was associated with a greater risk of diabetes when compared with moderate dosing.[40]

The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab (Praluent), was approved by the FDA in July 2015. It is indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C.

Alirocumab was approved before the completion of its CV-outcomes trial. The primary outcome measures for ODYSSEY-Outcomes,[41]  which is scheduled to finish by December 2017, include possible first occurrence of CHD death, any nonfatal MI, fatal and nonfatal ischemic stroke, and unstable angina requiring hospitalization. Secondary measures included time to first occurrence of any CHD event, major CHD event, any CV event, and all-cause mortality.

Alirocumab’s approval was based on data from the pivotal Phase 3 ODYSSEY program, which showed consistent, positive results for alirocumab compared to placebo and included current standard of care therapy (statins). The ODYSSEY LONG TERM trial evaluated alirocumab 150 mg SC every 2 weeks. Alirocumab reduced LDL cholesterol by 58% compared with placebo at week 24 when added to current standard of care, including maximally tolerated statins.[42] In ODYSSEY COMBO I, Praluent 75 mg every 2 weeks as an adjunct to statins reduced LDL cholesterol by an additional 45% compared with placebo at week 12.[43] At week 24 in the same trial, alirocumab reduced LDL cholesterol by an additional 44% compared with placebo. In this study, if additional LDL cholesterol lowering was required based on prespecified criteria at week 8, alirocumab was up-titrated to 150 mg at week 12 for the remainder of the trial. Eighty-three percent of patients remained on their initial 75 mg dose.

Evolocumab (Repatha) is the second PCSK9 inhibitor approved in the United States in 2015. It is approved for adults as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic CVD who require additional lowering of LDL-C. It is also approved for adults and adolescents with homozygous familial hypercholesterolemia (HoFH).

Approval of evolocumab was based on the Open-Label Study of Long-term Evaluation Against LDL-C (OSLER) study. During approximately 1 year of therapy, the use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels.[33, 34] Additionally, the rate of cardiovascular events at 1 year was reduced from 2.18% in the standard-therapy group to 0.95% in the evolocumab group (hazard ratio in the evolocumab group, 0.47; 95% confidence interval, 0.28 to 0.78; P=0.003) in a prespecified exploratory analysis.[33] Results of the ongoing FOURIER trial is looking at cardiovascular outcomes and will include more than 27,000 patients with clinically evident cardiovascular disease and is expected to be completed in late 2017.[35]

In pediatric heterozygous FH, a study suggests rosuvastatin slows atherosclerotic progression. In a randomized study (CHARON trial) of 196 children and adolescents (age range, 6-17 y) with heterozygous FH and 65 unaffected sibling controls, treatment with rosuvastatin in affected patients for two years slowed the progression of subclinical atherosclerosis.[44, 45, 46]  At baseline, the mean carotid intima-media thickness (IMT) was significantly higher among those with heterozygous FH (0.398 mm) compared with their healthy siblings (0.376 mm); following 2 years of treatment with rosuvastatin, there was no difference in the mean carotid IMT between the groups, and 38% of those receiving rosuvastatin met the target LDLc of less than 110 mg/dL.[44]  Over 85% of patients in the treatment group reported adverse events that the investigators considered as mild (eg, headaches, nasopharyngitis, influenzalike symptoms). All patients remained within the normal height and weight range for their age.[44]

Fibrates have no place in treatment of patients with FH unless triglyceride levels are elevated.

Estrogen replacement therapy in postmenopausal women also helps lower LDLc levels, but this therapy is not recommended because of its adverse effects in older women, although the benefits may sometimes outweigh risks.

Patients with documented CHD whose LDLc level cannot be lowered below 200 mg/dL by conventional therapy are candidates for LDL apheresis. Patients without CHD but with an LDLc level of higher than 300 mg/dL also qualify for this intervention. However, health insurance coverage is not automatic, and decisions are made on a case-by-case basis because of the costs, which approach $3000 for each treatment, every 2 weeks, for the patient's lifetime.

Previous
Next

Surgical Care

Liver transplantation for homozygous FH

Liver transplantation is rarely performed because of the considerable risks associated with the surgery itself and long-term immunosuppression. But a new liver provides functional LDL receptors and causes dramatic decreases in LDLc levels.

If not normalized, LDLc levels then can be treated with the usual LDL-lowering medications.

Portacaval anastomosis for homozygous FH

This may be indicated.

Previous
Next

Consultations

Homozygous FH

Because the risk of sudden death or nonfatal myocardial infarction is so high, early or highly specialized treatment is necessary.

As soon as a child is diagnosed with homozygous FH, a referral should be made to a medical center specializing in severe lipid disorders.

Referral to center providing LDL apheresis

Heterozygous FH

Refer to qualified nutritionist to provide guidance in reducing intake of saturated and trans fats and cholesterol and assist in weight reduction if indicated.

If patients do not reach recommended treatment goals under the care of their primary care physicians, they should be referred to an endocrinologist or lipid specialist and to a qualified nutritionist.

If patients are considered candidates for LDL apheresis and are willing to undertake this arduous procedure, referral should be made to a medical facility offering this procedure.

Previous
Next

Diet

Predicting the degree of improvement in an individual's lipids levels with dietary change is difficult because many variables affect the response, including the makeup of the baseline diet, the degree of patient compliance, and the individual's LDL responsiveness to the diet, which is genetically determined. A decrease of at least 15% can be expected in heterozygous patients who are willing to make significant dietary changes.

The 2001 NCEP ATPIII guidelines emphasize a multifaceted approach to the prevention of CHD.[6] Designated therapeutic lifestyle changes (TLC), its features include increased physical activity, weight reduction, and diet modification. The same diet is recommended for all patients with lipid abnormalities.

The NCEP recommendations for the dietary management of hypercholesterolemia are not highly restrictive, but a more stringent regimen may have a greater impact on lipid levels (see Table 2).

Restricting total fat is less important than reducing the intake of saturated fat, trans fat, and cholesterol. Moreover, diets very low in total fat are high in carbohydrates, which may increase triglyceride levels and lower HDLc levels. Substituting monounsaturated fats (eg, olive and canola oils, avocados, nuts) for carbohydrates does not increase LDLc levels and, in the absence of weight gain, may increase HDLc levels and lower triglyceride levels in patients who have maintained a diet very low in fat.

Diets should be rich in whole grains, whole fruit, and legumes and other vegetables. These foods are high in soluble fiber, which has a small (approximately 5%) cholesterol-lowering effect; they are also high in antioxidants and flavonoids, which may be cardioprotective.

Table 2. Recommended Dietary Intake (Open Table in a new window)

 



Food Category



 



Typical US Diet



 



NCEP Diet



 



Diet for FH



Cholesterol, mg/d 500 < 200 100
Total fat, % energy (calories) 40 25-35 20
Saturated fat, % energy (calories) 14 < 7 < 6
Carbohydrate, % energy (calories) 45 50-60 65
Protein, % energy (calories) Approximately 15 15 N/A

 

Other features of the NCEP diet are as follows:

  • Fiber (soluble fiber): Intake should be 20-30 g/d.
  • Carbohydrates: Intake should be 50-60% of total energy (caloric) intake. Carbohydrates should be derived predominantly from foods rich in complex carbohydrates, including grains, especially whole grains, fruits, and vegetables.
  • Plant sterols and stanols: Intake should be 2 g/d. [26] These are present in commercial margarines (eg, Benacol, Take Control).
  • Total energy (caloric) intake: Balance energy intake and expenditure to maintain desirable body weight and prevent weight gain. Daily energy expenditure should include at least moderate physical activity, contributing approximately 200 Kcal/d (eg, a brisk walk of 2 miles or more).
  • Trans- fatty acids ( trans fats): Intake should be avoided. Products made with hydrogenated fats contain variable amounts of trans fats. Similar to saturated fats, trans fats increase LDLc levels. However, unlike saturated fats, trans fats decrease HDLc levels. Hydrogenated fats and trans fats are found in many margarines, cakes, cookies, crackers, and frosting.
Previous
Next

Activity

Exercise has many cardiovascular benefits and can improve blood lipid levels. Although a greater proportion of time should be spent doing aerobic exercise because of its greater impact on lowering blood pressure and decreasing insulin resistance, resistance training also has benefits.

Patients with CAD or symptoms suggestive of ischemic heart disease should undergo a symptom-limited exercise stress test before undertaking a new program of vigorous exercise.

Previous
 
 
Contributor Information and Disclosures
Author

Mose July, MD Fellow in Endocrinology, Diabetes and Metabolism, Marshall University School of Medicine

Mose July, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society

Disclosure: Nothing to disclose.

Coauthor(s)

Omolola Bolaji Olajide, MD, FACE Associate Professor, Consultant, Department of Internal Medicine, Program Director, Fellowship Program, Section of Endocrinology, Joan C Edwards School of Medicine at Marshall University

Omolola Bolaji Olajide, MD, FACE is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, Endocrine Society, International Society for Clinical Densitometry

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Yoram Shenker, MD Chief of Endocrinology Section, Veterans Affairs Medical Center of Madison; Interim Chief, Associate Professor, Department of Internal Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Wisconsin at Madison

Yoram Shenker, MD is a member of the following medical societies: American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

Romesh Khardori, MD, PhD, FACP Professor of Endocrinology, Director of Training Program, Division of Endocrinology, Diabetes and Metabolism, Strelitz Diabetes and Endocrine Disorders Institute, Department of Internal Medicine, Eastern Virginia Medical School

Romesh Khardori, MD, PhD, FACP is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, Endocrine Society

Disclosure: Nothing to disclose.

Additional Contributors

Gregory William Rutecki, MD Professor of Medicine, Fellow of The Center for Bioethics and Human Dignity, University of South Alabama College of Medicine

Gregory William Rutecki, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society of Nephrology, National Kidney Foundation, Society of General Internal Medicine

Disclosure: Nothing to disclose.

References
  1. Illingworth DR, Duell PB, Connor WE. Disorders of lipid metabolism. Felig P, Baxter JD, Frohmin LA, eds. Endocrinology and Metabolism. 1315-1403.

  2. Ueda M. Familial hypercholesterolemia. Mol Genet Metab. 2005 Dec. 86(4):423-6. [Medline].

  3. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003 May. 168(1):1-14. [Medline].

  4. Wood S. New EAS Consensus Document Tackles Familial Hypercholesterolemia. Medscape Medical News. Available at http://www.medscape.com/viewarticle/805252. Accessed: September 5, 2013.

  5. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J. 2013 Aug 15. [Medline].

  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16. 285(19):2486-97. [Medline].

  7. National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med. 1988 Jan. 148(1):36-69. [Medline].

  8. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13. 110(2):227-39. [Medline].

  9. Connor WE, Connor SL. Dietary treatment of familial hypercholesterolemia. Arteriosclerosis. 1989 Jan-Feb. 9(1 Suppl):I91-105. [Medline].

  10. Illingworth DR. Management of hypercholesterolemia. Med Clin North Am. 2000 Jan. 84(1):23-42. [Medline].

  11. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001 Nov 29. 345(22):1583-92. [Medline].

  12. Toklu B, Amirian J, Giugliano RP. Current indications, cost, and clinical use of anti-PCSK9 monoclonal antibodies. American College of Cardiology. Available at http://www.acc.org/latest-in-cardiology/articles/2016/05/18/14/34/current-indications-cost-and-clinical-use-of-anti-pcsk9-monoclonal-antibodies. May 19, 2016; Accessed: July 10, 2016.

  13. Wiegman A et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015 Sep 21. 36 (36):2425-37. [Medline]. [Full Text].

  14. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004 Sep 1. 160(5):421-9. [Medline].

  15. Sibley C, Stone NJ. Familial hypercholesterolemia: a challenge of diagnosis and therapy. Cleve Clin J Med. 2006 Jan. 73(1):57-64. [Medline].

  16. Bjorkhem I, Boberg KM. Inborn errors in bile acid biosynthesis and storage of sterols other than cholesterol. Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001. 2073-2099.

  17. Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001 May 18. 292(5520):1394-8. [Medline].

  18. Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001. 2717-2752.

  19. Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation. 1987 Sep. 76(3):504-7. [Medline].

  20. Goldstein JL, Brown MS. Molecular medicine. The cholesterol quartet. Science. 2001 May 18. 292(5520):1310-2. [Medline].

  21. Hammond E, Watts GF, Rubinstein Y, et al. Role of international registries in enhancing the care of familial hypercholesterolaemia. Int J Evid Based Healthc. 2013 Jun. 11(2):134-9. [Medline]. [Full Text].

  22. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation. 2016 Mar 15. 133 (11):1067-72. [Medline].

  23. Khachadurian AK, Uthman SM. Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutr Metab. 1973. 15(1):132-40. [Medline].

  24. Pisciotta L, Priore Oliva C, Pes GM, Di Scala L, Bellocchio A, Fresa R, et al. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis. 2006 Oct. 188(2):398-405. [Medline].

  25. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993 Jul 15. 72(2):171-6. [Medline].

  26. Patel MD, Thompson PD. Phytosterols and vascular disease. Atherosclerosis. 2006 May. 186(1):12-9.

  27. [Guideline] Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011 Jul. 217(1):3-46. [Medline].

  28. [Guideline] Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1. 63 (25 Pt B):2889-934. [Medline]. [Full Text].

  29. European Atherosclerosis Society. New EAS Consensus Panel Statement on Homozygous FH. Available at http://www.eas-society.org/02-2014---consensus-on-homozygous-fh.aspx. Accessed: August 8, 2014.

  30. FDA Approves Atorvastatin/Ezetimibe Combo Tablet. Medscape. May 3 2013. [Full Text].

  31. Richter WO, Donner MG, Hofling B, Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism. 47(7):863-8. [Medline].

  32. Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis. 2006 Mar 16. [Epub ahead of print].

  33. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16. 372 (16):1500-9. [Medline].

  34. Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014 Jan 14. 129 (2):234-43. [Medline]. [Full Text].

  35. Langslet G, Emery M, Wasserman SM. Evolocumab (AMG 145) for primary hypercholesterolemia. Expert Rev Cardiovasc Ther. 2015 May. 13 (5):477-88. [Medline].

  36. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2012 Nov 1. [Medline].

  37. Nainggolan L. Mipomersen Approved in US for Homozygous FH. Available at http://www.medscape.com/viewarticle/778465. Accessed: February 12, 2013.

  38. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20. 375(9719):998-1006. [Medline].

  39. Kane JP, Malloy MJ, Tun P, Phillips NR, Freedman DD, Williams ML, et al. Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med. 1981 Jan 29. 304(5):251-8. [Medline].

  40. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22. 305(24):2556-64. [Medline].

  41. ODYSSEY outcomes: Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727). ClinicalTrials.gov. NCT01663402. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT01663402. 2015 Jul 10; Accessed: July 27, 2015.

  42. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16. 372 (16):1489-99. [Medline].

  43. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015 Jun. 169 (6):906-915.e13. [Medline]. [Full Text].

  44. O'Riordan M. Rosuvastatin slows atherosclerosis in FH kids. Heartwire. June 6, 2014. [Full Text].

  45. Braamskamp M, Langslet G, McCrindle BW, et al. Efficacy and safety of rosuvastatin in children aged 6–17 years with familial hypercholesterolemia: findings from the CHARON study (abstract M140). Presented at EAS 2014: The 82nd European Atherosclerosis Society Congress; June 2, 2014; Madrid, Spain.

  46. Braamskamp MJAM, Langslet G, McCrindle BW, et al. Effect of rosuvastatin therapy on carotid intima media thickness in children with familial hypercholesterolemia: findings from the CHARON study. Presented at EAS 2014: The 82nd European Atherosclerosis Society Congress; June 3, 2014; Madrid, Spain.

  47. Cohen DE, Anania FA, Chalasani N,. An assessment of statin safety by hepatologists. Am J Cardiol. 2006 Apr 17. 97(8A):77C-81C. [Medline].

  48. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19. 344(8934):1383-9. [Medline].

  49. Jones PH, Davidson MH, Stein EA. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 Jul 15. 92(2):152-60. [Medline].

  50. Thompson PD, Clarkson PM, Rosenson RS, National Lipid Association Statin Safety Task Force Liver Exert Panel. An assessment of statin safety by muscle experts. Am J Cardiol. 2006 Apr 17. 97(8A):69C-76C.

  51. Bulbulia R, Bowman L, Wallendszus K, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011 Dec 10. 378(9808):2013-20. [Medline]. [Full Text].

  52. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, et al. Apolipoprotein B Synthesis Inhibition with Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo Controlled Trial to Assess Efficacy and Safety as Add-on Therapy in Patients with Coronary Artery Disease. Circulation. 2012 Oct 11. [Medline].

  53. McKenney JM, Davidson MH, Jacobson TA, Guyton JR, National Lipid Association Statin Safety Task Force Liver Expert Panel. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006 Apr 17. 97(8A):89C-94C.

  54. Wending P. FDA pulls approval of niacin, fibrate in combo with statins. Heartwire. 2016 Apr 15. Available at http://www.medscape.com/viewarticle/862022.

  55. Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis. 2006 Feb 6. [Epub ahead of print].

  56. Aegerion Pharmaceuticals. FDA approves Aegerion Pharmaceuticals' Juxtapid (lomitapide) capsules for homozygous familial hypercholesterolemia (HoFH) [press release]. December 24, 2012. Available at http://ir.aegerion.com/releasedetail.cfm?ReleaseID=728650. Accessed: January 10, 2013.

  57. Buchwald H, Matts JP, Fitch LL, Campos CT, Sanmarco ME, Amplatz K, et al. Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA. 1992 Sep 16. 268(11):1429-33. [Medline].

  58. Nainggolan L. Lomitapide approved for homozygous familial hypercholesterolemia. Medscape Medical News. December 24, 2012. Available at http://www.medscape.com/viewarticle/776699. Accessed: January 10, 2013.

  59. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003. 111(12):1795-803. [Medline]. [Full Text].

  60. Zuliani G, Vigna GB, Corsini A, Maioli M, Romagnoni F, Fellin R. Severe hypercholesterolaemia: unusual inheritance in an Italian pedigree. Eur J Clin Invest. 1995 May. 25(5):322-31. [Medline].

 
Previous
Next
 
Metacarpophalangeal joint tendon xanthomas in a 45-year-old man with heterozygous familial hypercholesterolemia.
Table 1. LDLc Target levels and levels Indicating Therapeutic Lifestyle Changes (TLC) and Drug Therapy
 



Risk Category



 



LDLc Target level,



mg/dL



 



LDLc level Indicating TLC,



mg/dL



 



LDLc level for Considering Drug Therapy,



mg/dL*



High risk:



CHD or CHD risk equivalent



(10-y risk >20%)



<100



Optional goal <70



>100 >100
Moderately high risk:



More than 2 risk factors



(10-y risk 10-20%)



130



Optional goal <100



>130 >130



(100-129 may consider drug options)



Moderate risk:



More than 2 risk factors



(10-y risk 10%)



<130 >130 >160
Lower risk:



0-1 risk factor



<160 >160 >190



(160-189 LDL-lowering drug optional)



*The 2004 update recommended that when statin therapy is initiated in patients at high or moderately high risk, a dose and strength should be chosen that achieves at least a 30-40% LDLc reduction (see Table 3).
Table 2. Recommended Dietary Intake
 



Food Category



 



Typical US Diet



 



NCEP Diet



 



Diet for FH



Cholesterol, mg/d 500 < 200 100
Total fat, % energy (calories) 40 25-35 20
Saturated fat, % energy (calories) 14 < 7 < 6
Carbohydrate, % energy (calories) 45 50-60 65
Protein, % energy (calories) Approximately 15 15 N/A
Table 3. Statin and Statin Combination Approved Doses, Expected LDLc Decrease, and Dose Required for 30-40% LDLc Reduction
 



Statin



 



FDA-Approved Dose



 



Expected LDLc Decrease



 



Dose Required for 30-40% LDLc Reduction



Atorvastatin 10-80 mg daily 35-60% 10 mg
Fluvastatin 20-40 mg at bedtime 20-30% 40 mg qd/bid
40 mg bid 35% 40 mg bid
Extended-release fluvastatin



(Lescol XL)



80 mg at bedtime 35-38% 80 mg at bedtime
Lovastatin 20-80 mg at supper 25-48% 40 mg at dinner
Extended-release lovastatin



(Altoprev)



20-60 mg at bedtime 25-45% 60 mg at bedtime
Pravastatin 40-80 mg at bedtime 30-40% 40 mg at bedtime
Rosuvastatin 10-40 mg daily 40-60% 5 mg daily
Simvastatin 20-80 mg daily at bedtime 35-50% 20 mg at bedtime
Simvastatin + ezetimibe



(Vytorin)



10/20 mg



10/40 mg



10/80 mg



at bedtime



50-60% 10/20 mg at bedtime
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.